telmisartan has been researched along with ramipril in 162 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 84 (51.85) | 29.6817 |
| 2010's | 73 (45.06) | 24.3611 |
| 2020's | 5 (3.09) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sleight, P | 3 |
| Yusuf, S | 1 |
| Weber, MA | 3 |
| Hankey, GJ | 1 |
| Probstfield, JL | 1 |
| Unger, T | 1 |
| Matos, L | 1 |
| Unger, T; Zimmermann, M | 1 |
| Anderson, C; Hilbrich, L; Mookadam, F; Pogue, J; Ramos, B; Schumacher, H; Sleight, P; Teo, K; Yusuf, S | 1 |
| de Champlain, J; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; Poirier, L | 1 |
| de Champlain, J; Karas, M; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; Poirier, L | 1 |
| Atkinson, J; Chillon, JM; Dupuis, F; Limiñana, P | 1 |
| de Champlain, J; Dubé, B; Florescu, M; Karas, M; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; LeBlanc, AR; Nadeau, R; Poirier, L | 1 |
| El-Ali, M; Ioannidis, G; Karabinos, I; Katostaras, T; Kokkinou, V; Koulouris, S; Nanas, I; Stamatelopoulos, S; Symeonides, P; Thalassinos, N; Theodoridis, T; Toutouzas, P; Triantafyllou, K; Vratsista, E | 1 |
| Amasyali, B; Celik, T; Demirkol, S; Isik, E; Iyisoy, A; Kilic, S; Kose, S; Kursaklioglu, H; Yilmaz, MI | 1 |
| Bley, S; Drexler, H; Grote, K; Grothusen, C; Luchtefeld, M; Schieffer, B; Selle, T; Tietge, UJ | 1 |
| Babic, R; Dragicevic, J; Petrovic, D; Petrovic, I; Vasiljevic, Z; Vukovic, N; Zivanovic, B | 1 |
| Anderson, C | 1 |
| Gosse, P; Harper, R; Lowe, L; Williams, B | 1 |
| Davidai, G; Koval, S; Lacourcière, Y; Neutel, JM | 1 |
| Ioannidis, G; Katritsis, D; Koulouris, S; Symeonides, P; Thalassinos, N; Triantafyllou, K; Vratsista, E | 1 |
| Delles, C; Fauvel, JP; Mimran, A; Ruilope, LM; Schmieder, RE | 1 |
| Anderson, C; Gerstein, HC; Held, C; Hilbrich, L; Sleight, P; Teo, K; Yusuf, S; Zhao, F | 1 |
| Davidai, G; Gosse, P; Lacourcière, Y; Neutel, JM; Schumacher, H; Williams, B | 1 |
| Baumhäkel, M; Böhm, M; Koon, T; Probstfield, JL; Schmieder, R; Yusuf, S; Zhao, F | 1 |
| Stoppelhaar, M; Unger, T | 1 |
| Fitchett, D | 1 |
| Anderson, C; Copland, I; Dagenais, G; Dyal, L; Pogue, J; Schumacher, H; Sleight, P; Teo, KK; Yusuf, S | 1 |
| McMurray, JJ | 1 |
| Heroys, J; Jakobsen, A; Mancia, G; Ralph, A; Rees, T; Shaw, M | 1 |
| Balduini, CL; Fiore, CE; Granata, A; Pecci, A | 1 |
| Liakishev, AA | 1 |
| Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S | 2 |
| Krzesinski, JM; Scheen, AJ | 1 |
| Dahlöf, B; Ritz, E | 1 |
| Burnier, M; Hess, O; Lüscher, T; Waeber, B | 1 |
| Banas, B; Büchner, N; Krämer, BK | 1 |
| Bangalore, S; Messerli, FH; Ram, VS | 1 |
| van den Meiracker, AH | 1 |
| Cohn, JN | 1 |
| Düsing, R; Nitschmann, S | 1 |
| Bakris, GL; Sarafidis, PA | 1 |
| Budaj, A; Chaithiraphan, S; Dickstein, K; Dyal, L; Keltai, M; Maggioni, A; Mann, JF; McQueen, M; Metsärinne, K; Oto, A; Parkhomenko, A; Piegas, LS; Pogue, J; Schmieder, RE; Schumacher, H; Svendsen, TL; Teo, KK; Wang, X; Yusuf, S | 1 |
| Baliga, V; Sharma, A | 1 |
| Atar, D; Hanley, DF; Serebruany, VL | 1 |
| Einecke, D | 1 |
| Shi, XY; Xi, GL; Yuan, HB; Zhu, QF; Zou, Z | 1 |
| Delles, C; Fauvel, JP; Mimran, A; Raff, U; Ruilope, LM; Schmieder, RE | 1 |
| Fischer, P; Masnatta, LD; Pesiney, C; Ramirez, AJ; Sanchez, RA | 1 |
| Hilgers, KF; Ott, C; Raff, U; Ritt, M; Schlaich, MP; Schmieder, RE; Schneider, MP; Schuster, I | 1 |
| Schindler, C | 1 |
| Weder, AB | 1 |
| Anderson, C; Cukierman-Yaffe, T; Gerstein, HC; Hilbrich, L; Jackson, SH; Sleight, P; Teo, K; Yusuf, S; Zhao, F | 1 |
| Gosse, P; Lacourcière, Y; Neutel, JM; Schumacher, H; Williams, B | 1 |
| Albert, DH; Banfor, PN; Cox, BF; Davidsen, SK; Franklin, PH; Fryer, RM; Gintant, GA; Larson, KJ; Noonan, WT; Segreti, JA; Tapang, P; Widomski, DL | 1 |
| Amsterdam, EA; Liebson, PR | 1 |
| Anderson, C; Cowan, BR; Doughty, RN; Jennings, GL; Krittayaphong, R; Lonn, E; Marwick, TH; Reid, CM; Sanderson, JE; Schmieder, RE; Teo, K; Wadham, AK; Worthley, SG; Young, AA; Yu, CM; Yusuf, S | 2 |
| Terrosu, P; Verdecchia, P | 1 |
| Richard Conti, C | 1 |
| Guthrie, R | 1 |
| Biasucci, LM; Capogrossi, MC; Crea, F; Dato, I; De Maria, GL; Di Vito, L; Leone, AM; Niccoli, G; Porto, I; Tritarelli, A | 1 |
| Elliott, HL | 1 |
| Böhm, M; Fagard, R; Gao, P; Koon, T; Mancia, G; Pogue, J; Redon, J; Schumacher, H; Sleight, P; Verdecchia, P; Weber, M; Williams, B; Yusuf, S | 1 |
| Mancia, G; Unger, T; Zanchetti, A | 1 |
| Diener, HC | 1 |
| Ferrari, R | 1 |
| Weber, M | 1 |
| Remuzzi, G; Ruggenenti, P | 1 |
| Basile, J | 1 |
| Chen, JH; Fagard, R; Gao, P; Jansky, P; Jennings, G; Kim, JH; Liu, L; Mancia, G; Probstfield, J; Schmieder, RE; Sleight, P; Teo, K; Trimarco, B; Verdecchia, P; Yusuf, S | 1 |
| Mann, JF; Teo, KK; Tobe, S; Yusuf, S | 1 |
| Baumhäkel, M; Böhm, M | 1 |
| Abutaleb, N | 1 |
| Neldam, S | 1 |
| Oğuz, A | 1 |
| Biasucci, LM; Capogrossi, MC; Crea, F; Dato, I; De Maria, GL; Di Vito, L; Leone, AM; Paglia, A; Porto, I; Tritarelli, A | 1 |
| Hoogwerf, BJ | 1 |
| Baumhäkel, M; Böhm, M; Dagenais, GR; Diaz, R; Gao, P; Jansky, P; Jennings, GL; Liu, L; Mann, JF; Probstfield, J; Sleight, P; Teo, K; Yusuf, S | 1 |
| Barrios, V; Echarri, R; Escobar, C | 1 |
| Capogrosso, C; Di Michele, S; Galzerano, A; Galzerano, D; Gaudio, C; Lama, D; Paparello, P | 1 |
| de Boer, IH; Pichler, RH | 1 |
| Budzyn, K; Drummond, GR; Sobey, CG | 1 |
| Atkinson, J; Capdeville-Atkinson, C; Chillon, JM; Dupuis, F; Limiñana, P; Vincent, JM | 1 |
| Anantharaman, R; Bhadada, SK; Bhansali, A; Dutta, P; Jayaprakash, P; Kohli, HS; Upreti, V; Walia, R | 1 |
| Bilo, G; Mancia, G; Parati, G; Schumacher, H | 1 |
| Pollock, CA; Ritz, E; Schmieder, RE | 1 |
| Anderson, C; Arima, H; Binbrek, A; Chazova, I; Commerford, P; Dans, A; Dyal, L; Gao, P; Holwerda, N; Paolasso, E; Pogue, J; Schumacher, H; Teo, K; Unger, T; Young, J; Yusuf, S | 1 |
| Baumhäkel, M; Böhm, M; Mahfoud, F; Werner, C | 1 |
| Agarwal, S; Dwivedi, A; Gupta, VK; Jain, R; Lukram, O | 1 |
| Guthrie, RM | 1 |
| Chaithiraphan, S; Chen, JH; Dans, AL; Gao, P; Jae-Hyung, K; Lisheng, L; Teo, K; Yusoff, K; Yusuf, S; Zhu, J | 1 |
| Baumhäkel, M; Böhm, M; Kratz, M; Schlimmer, N | 1 |
| Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Clase, CM; Gao, P; Grosshennig, A; Mann, JF; McQueen, M; Teo, KK; Tobe, SW; Wang, X; Yusuf, S | 1 |
| Ruilope, LM; Segura, J; Zamorano, JL | 1 |
| Ruilope, LM | 1 |
| Liu, LS; Tan, HQ; Teo, KK; Wang, GG; Yu, LT; Zhu, J | 1 |
| Arfa, O; Czech, T; Ebrahimian, T; Endtmann, C; Fritz, M; Laufs, U; Nickenig, G; Petoumenos, V; Wassmann, K; Wassmann, S; Werner, N | 1 |
| Godes, M; Krikov, M; Mueller, S; Namsolleck, P; Rumschüssel, K; Schmerbach, K; Steckelings, U; Thoene-Reineke, C; Unger, T; Villringer, A; Wengenmayer, C | 1 |
| Jennings, G; Liu, GL; Mancia, G; Redon, J; Ryden, L; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Verdecchia, P; Yusoff, K; Yusuf, S | 1 |
| Avezum, A; Dans, A; Ferreira, R; Gafni, A; Gao, P; Lamy, A; Teo, K; Tong, W; Wang, X; Young, J; Yusuf, S | 1 |
| Chalmers, J | 1 |
| Jöhren, O; Miesel, A; Müller-Fielitz, H; Raasch, W; Vogt, FM | 1 |
| Böhm, M; Fagard, R; Gao, P; Mancia, G; Pogue, J; Redon, J; Schumacher, H; Sleight, P; Teo, K; Verdecchia, P; Weber, M; Williams, B; Yusoff, K; Yusuf, S | 1 |
| Anantharaman, R; Bhadada, SK; Bhansali, A; Jayaprakash, P; Kohli, HS; Shanmugasundar, G; Walia, R | 1 |
| Danser, AH; Maggioni, AP; Menard, J; Mueller, DN; Ruilope, LM; Volpe, M; Waeber, B | 1 |
| Trenkwalder, P | 1 |
| Böhm, M; Friedrich, EB; Jagoda, P; Kazakov, A; Laufs, U; Müller, P; Semenov, A | 1 |
| Hollenberg, NK | 1 |
| Kjeldsen, SE; Okin, PM | 1 |
| Binbrek, AS; Chazova, I; Dagenais, G; Dans, AL; Ferreira, R; Gao, P; Healey, J; Holwerda, N; Iacobellis, G; Karatzas, N; Keltai, M; Mancia, G; Sleight, P; Teo, K; Verdecchia, P; Yusuf, S | 1 |
| Grassi, B; Neumann, I | 1 |
| Böhm, M; Kappert, K; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S | 1 |
| Hocher, B; Kalk, P; Lucht, K; Schmerbach, K; Thoene-Reineke, C; Unger, T; Wengenmayer, C | 1 |
| Bilo, G; Czuriga, I; Fagard, R; Gao, P; Mancia, G; Parati, G; Polák, M; Redon, J; Ribeiro, JM; Sanchez, R; Sleight, P; Teo, K; Trimarco, B; van Mieghem, W; Verdecchia, P; Yusuf, S | 1 |
| Middeke, M | 1 |
| Barzilay, JI; Clase, CM; Gao, P; Mann, JF; Mente, A; Sleight, P; Teo, KK; Yusuf, S | 1 |
| Agarwal, M; Chugh, PK; Gupta, M; Tekur, U | 1 |
| Huang, Z; Nyström, T; Olverling, A; Sjöholm, Å | 1 |
| Anand, SS; Bradford, Y; Brown, NJ; Byrd, JB; Kubo, M; McCarty, CA; Nakamura, Y; Pare, G; Ritchie, M; Ross, S; Teo, KK; Woodard-Grice, A; Zuvich, RL | 1 |
| Böhm, M; Laufs, U; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S | 1 |
| Chang, A; Kramer, H | 1 |
| Clase, CM; Dehghan, M; Dunkler, D; Gao, P; Heinze, G; Kohl, M; Mann, JF; Oberbauer, R; Teo, KK; Yusuf, S | 1 |
| Gosse, P; Schumacher, H | 1 |
| Li, L; Liu, LM; Tan, LL; Zhao, HL | 1 |
| Clase, C; Dagenais, GR; de Zeeuw, D; Gao, P; Heerspink, HJ; Lonn, E; Mann, JF; Sleight, P; Teo, KT; Yusuf, S | 1 |
| Anderson, C; Bosch, J; Gao, P; Joseph, PG; Khatib, R; O'Donnell, MJ; Probstfield, JL; Teo, KK; Yusuf, S | 1 |
| Lackland, DT | 1 |
| Angeli, F; Gao, P; Mancia, G; Pogue, J; Reboldi, G; Sleight, P; Teo, K; Trimarco, B; Verdecchia, P; Yusuf, S | 1 |
| Basile, JN; Gradman, AH | 1 |
| Angeloni, E; Lombardo, P; Pirelli, M; Refice, S; Vitaterna, A | 1 |
| Anderson, C; Böhm, M; Custodis, F; Diener, HC; Fagard, R; Laufs, U; Leong, D; Lonn, E; Mancia, G; O'Donnell, M; Redon, J; Schmieder, R; Schumacher, H; Sleight, P; Sliwa, K; Teo, K; Unger, T; Yusuf, S | 1 |
| Anderson, C; Cukierman-Yaffe, T; Gao, P; Gerstein, HC; Teo, K; Yusuf, S | 1 |
| Chen, CH; Cheng, HM; Hoshide, S; Huang, QF; Kario, K; Park, CG; Park, S; Wang, JG | 1 |
| Arru, D; Assaretti, S; Baralla, A; Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A | 1 |
| Barzilay, J; Clase, CM; Gao, P; Mann, JF; Schmieder, RE; Smyth, A; Teo, KK; Tobe, S; Yusuf, S | 1 |
| Böhm, M; Lonn, EM; Mahfoud, F; Mancia, G; Mann, JFE; Redon, J; Schmieder, RE; Schumacher, H; Sliwa, K; Teo, KK; Weber, MA; Williams, B; Yusuf, S | 1 |
| Avorn, J; Fralick, M; Kesselheim, AS; Schneeweiss, S | 1 |
| Böhm, M; Lonn, E; Mahfoud, F; Mancia, G; Mann, JFE; Redon, J; Schmieder, R; Schumacher, H; Sliwa, K; Teo, KK; Weber, M; Williams, B; Yusuf, S | 1 |
| Böhm, M; Lonn, EM; Mahfoud, F; Mancia, G; Mann, JFE; Marx, N; Redon, J; Schmieder, RE; Schumacher, H; Sliwa, K; Teo, KK; Weber, MA; Williams, B; Yusuf, S | 1 |
| AlHabib, KF; Altuntas, Y; Anand, SS; Avezum, A; Chifamba, J; Dans, A; Dehghan, M; Diaz, R; Gupta, R; Iqbal, R; Ismail, N; Kaur, M; Khatib, R; Lear, S; Li, N; Liu, X; Lopez-Jaramillo, P; Mente, A; Mohammadifard, N; Mohan, V; Rangarajan, S; Rosengren, A; Seron, P; Sheridan, P; Smuts, M; Soman, B; Swaminathan, S; Szuba, A; Teo, K; Turbide, G; Wielgosz, A; Yusoff, K; Yusuf, R; Yusuf, S; Yusufali, A | 1 |
| Advani, A; Advani, SL; Batchu, SN; Kabir, MG; Kaur, H; Klein, T; Liu, Y; Yerra, VG | 1 |
| Aiglova, R; Cernicek, V; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M | 1 |
| Baptiste, PJ; Clase, C; Cunnington, M; Leyrat, C; Mann, JFE; Schultze, A; Tomlinson, LA; Wing, K; Wong, AYS | 1 |
| Kassie, GM; Kerr, M; Moffat, A; Pratt, N; Roughead, EE | 1 |
30 review(s) available for telmisartan and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Angiotensin II and trials of cardiovascular outcomes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Ramipril; Survival Rate; Telmisartan; Treatment Outcome | 2002 |
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Carotid Artery Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prognosis; Ramipril; Receptor, Angiotensin, Type 1; Telmisartan; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left | 2002 |
The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chronotherapy; Circadian Rhythm; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Telmisartan; Treatment Outcome | 2002 |
Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Humans; Hypertension; Life Style; Practice Guidelines as Topic; Ramipril; Risk; Risk Factors; Stroke; Telmisartan | 2003 |
How cost-effective are new preventive strategies for cardiovascular disease?
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Life Expectancy; Models, Econometric; Ramipril; Survival Analysis; Telmisartan; United States | 2003 |
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Ramipril; Renin-Angiotensin System; Telmisartan | 2003 |
[New possibilities in clinical use of angiotensin II receptor inhibitors].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Ramipril; Renin-Angiotensin System; Survival Analysis; Telmisartan; Treatment Outcome | 2003 |
Rationale for double renin-angiotensin-aldosterone system blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan | 2007 |
Clinical trial update: focus on the ONTARGET study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2007 |
Cardiac and vascular protection: the potential of ONTARGET.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiotonic Agents; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Therapy, Combination; Humans; Ramipril; Telmisartan; Treatment Outcome | 2008 |
Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Enalapril; Humans; Hypertension; Lisinopril; Models, Statistical; Perindopril; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome | 2009 |
Recent advances in cardiovascular risk reduction: implications of ONTARGET.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Risk Reduction Behavior; Telmisartan | 2009 |
Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Female; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan | 2009 |
Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hypertension; Ramipril; Telmisartan; Treatment Outcome | 2009 |
Lessons learned from the ONTARGET and TRANSCEND trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome; United States | 2009 |
Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Treatment Outcome | 2009 |
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Humans; Hypertension; Losartan; Ramipril; Risk Factors; Telmisartan; Tetrazoles | 2010 |
[Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Ramipril; Renin-Angiotensin System; Telmisartan | 2009 |
Renin-angiotensin system blockade and cardiovascular and renal protection.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Drug Therapy, Combination; Humans; Kidney Diseases; Ramipril; Telmisartan | 2010 |
Telmisartan in high-risk cardiovascular patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Humans; Kidney Diseases; Ramipril; Risk Factors; Telmisartan | 2010 |
New standards in hypertension and cardiovascular risk management: focus on telmisartan.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium Channel Blockers; Cardiovascular Diseases; Cardiovascular System; Humans; Hypertension; Ramipril; Risk Factors; Telmisartan | 2010 |
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Benzimidazoles; Benzoates; Diabetic Nephropathies; Humans; Hyperkalemia; Models, Biological; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan | 2010 |
Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Databases, Factual; Female; Humans; Losartan; Male; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Renal protection in diabetes: lessons from ONTARGET.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetic Nephropathies; Humans; Hypertension, Renal; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan | 2010 |
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Disease Progression; Humans; Ramipril; Risk Factors; Telmisartan; Treatment Outcome | 2010 |
Telmisartan for the management of patients at high cardiovascular risk.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cost of Illness; Heart Failure; Humans; Myocardial Infarction; PubMed; Ramipril; Telmisartan; Time Factors | 2011 |
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Ramipril; Renin; Renin-Angiotensin System; Telmisartan | 2012 |
Target Blood Pressure in Patients with Diabetes: Asian Perspective.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypotension; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Reference Values; Risk Factors; Stroke; Telmisartan | 2016 |
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Follow-Up Studies; Hospitalization; Humans; Hypertension; Hypotension; Male; Middle Aged; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2017 |
57 trial(s) available for telmisartan and ramipril
| Article | Year |
|---|---|
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Heart Diseases; Humans; Hypertension; Prognosis; Ramipril; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk Reduction Behavior; Telmisartan; Treatment Outcome | 2004 |
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmi
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Humans; Middle Aged; Patient Selection; Ramipril; Randomized Controlled Trials as Topic; Research Design; Telmisartan | 2004 |
A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Renin; Telmisartan; Therapeutic Equivalency | 2004 |
Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.
Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium Channel Blockers; Circadian Rhythm; Female; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Posture; Prospective Studies; Ramipril; Reference Values; Renin; Renin-Angiotensin System; Telmisartan; Treatment Outcome | 2005 |
The ONTARGET/TRANSCEND Trial Programme: baseline data.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Prospective Studies; Ramipril; Telmisartan | 2005 |
Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Epinephrine; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Ramipril; Renin-Angiotensin System; Telmisartan; Treatment Outcome | 2005 |
The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ramipril; Stroke Volume; Telmisartan; Treatment Outcome | 2005 |
Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Carotid Arteries; Drug Therapy, Combination; Echocardiography, Doppler; Female; Humans; Hypertension; Male; Middle Aged; Muscle, Smooth, Vascular; Ramipril; Retrospective Studies; Telmisartan; Time Factors; Tunica Intima; Tunica Media; Ventricular Remodeling | 2005 |
Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Middle Aged; Natriuretic Peptide, Brain; Patient Selection; Ramipril; Research Design; Telmisartan; Time Factors | 2005 |
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cough; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ramipril; Single-Blind Method; Telmisartan; Time Factors | 2006 |
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Humans; Hypertension; Longitudinal Studies; Male; Middle Aged; Ramipril; Single-Blind Method; Telmisartan | 2006 |
Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Flow Velocity; Cardiomyopathies; Cross-Over Studies; Diabetes Complications; Double-Blind Method; Echocardiography, Doppler; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Ramipril; Statistics, Nonparametric; Telmisartan; Treatment Outcome | 2007 |
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; Ramipril; Renal Circulation; Telmisartan | 2007 |
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Complications; Drug Therapy, Combination; Fasting; Female; Heart Failure; Hospitalization; Humans; Hyperglycemia; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Ramipril; Risk Factors; Telmisartan | 2007 |
The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Asian People; Benzimidazoles; Benzoates; Black People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Telmisartan; Time Factors; White People | 2007 |
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telm
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Erectile Dysfunction; Global Health; Humans; Male; Middle Aged; Multivariate Analysis; Patient Satisfaction; Prospective Studies; Ramipril; Risk Factors; Telmisartan | 2007 |
Telmisartan, ramipril, or both in patients at high risk for vascular events.
Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Ramipril; Risk; Telmisartan | 2008 |
[Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Drug Therapy, Combination; Female; Global Health; Humans; Incidence; Male; Peripheral Vascular Diseases; Ramipril; Risk Factors; Telmisartan; Treatment Outcome | 2008 |
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; Humans; Ramipril; Risk Factors; Telmisartan; Treatment Outcome; Vascular Diseases | 2008 |
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Proteinuria; Ramipril; Telmisartan | 2008 |
Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Female; Humans; Hypertension; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Ramipril; Telmisartan | 2008 |
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Female; Humans; Hypertension; Insulin Resistance; Lipids; Male; Oxidative Stress; PPAR gamma; Ramipril; Renin; Salt Tolerance; Telmisartan | 2008 |
Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Circadian Rhythm; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ramipril; Telmisartan | 2009 |
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Ramipril; Risk Factors; Telmisartan; Treatment Outcome | 2009 |
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Protocols; Double-Blind Method; Drug Therapy, Combination; Female; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Quality Control; Ramipril; Reproducibility of Results; Retrospective Studies; Stroke Volume; Telmisartan; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; C-Reactive Protein; Endothelium, Vascular; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Prospective Studies; Ramipril; Stem Cells; Telmisartan | 2009 |
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prognosis; Ramipril; Telmisartan; Treatment Outcome | 2009 |
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diastole; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Male; Odds Ratio; Placebos; Prevalence; Proportional Hazards Models; Ramipril; Regression Analysis; Systole; Telmisartan | 2009 |
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Diabetes Complications; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Ramipril; Survival Analysis; Telmisartan; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events.
Topics: AC133 Antigen; Acute Coronary Syndrome; Aged; Angiotensin-Converting Enzyme Inhibitors; Antigens, CD; Antigens, CD34; Benzimidazoles; Benzoates; C-Reactive Protein; Female; Flow Cytometry; Glycoproteins; Hematopoietic Stem Cells; Humans; Linear Models; Male; Middle Aged; Peptides; Prospective Studies; Ramipril; Recurrence; Telmisartan | 2011 |
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoler
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Mortality; Predictive Value of Tests; Ramipril; Telmisartan; Treatment Outcome | 2010 |
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Neuropsychological Tests; Odds Ratio; Ramipril; Renin-Angiotensin System; Telmisartan; Treatment Outcome | 2011 |
In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.
Topics: Angiotensin-Converting Enzyme Inhibitors; Asia; Benzimidazoles; Benzoates; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Ethnicity; Humans; Patient Compliance; Placebos; Ramipril; Risk; Telmisartan; Treatment Outcome | 2010 |
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; Benzoates; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Metabolic Syndrome; Prospective Studies; Ramipril; Secondary Prevention; Severity of Illness Index; Telmisartan; Treatment Outcome | 2012 |
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Ramipril; Stroke; Telmisartan; Treatment Outcome | 2011 |
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; China; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Ramipril; Telmisartan | 2011 |
Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Apoptosis; Benzimidazoles; Benzoates; Blood Vessels; Bone Marrow Transplantation; Cell Count; Cells, Cultured; Coronary Artery Disease; Double-Blind Method; Endothelial Cells; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Ramipril; Receptor, Angiotensin, Type 1; Regeneration; Stem Cells; Telmisartan; Vasoconstrictor Agents | 2011 |
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Incidence; Kidney Diseases; Middle Aged; Ramipril; Risk; Stroke; Telmisartan | 2011 |
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
Topics: Aged; Benzimidazoles; Benzoates; Blood Pressure Determination; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Hypotension; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Ramipril; Reference Values; Risk Assessment; Survival Rate; Telmisartan; Treatment Outcome | 2012 |
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleran
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anthropometry; Atrial Fibrillation; Benzimidazoles; Benzoates; Body Mass Index; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Middle Aged; Placebos; Ramipril; Risk; Risk Factors; Stroke; Telmisartan; Vitamin K | 2012 |
[Critically appraised article].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Middle Aged; Multicenter Studies as Topic; Proteinuria; Ramipril; Telmisartan | 2012 |
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combinatio
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Ramipril; Research Design; Risk Assessment; Risk Factors; Sex Distribution; Sex Factors; Stroke; Telmisartan | 2012 |
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female; Humans; Hypertension; Longitudinal Studies; Male; Middle Aged; Ramipril; Telmisartan; Treatment Outcome | 2012 |
Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Fractures, Bone; Glomerular Filtration Rate; Hip Fractures; Humans; Pelvic Bones; Prospective Studies; Ramipril; Risk Factors; Telmisartan; Time Factors | 2013 |
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Black or African American; Double-Blind Method; Drug Therapy, Combination; ETS Translocation Variant 6 Protein; Genome-Wide Association Study; Humans; Isoenzymes; Neprilysin; Polymorphism, Single Nucleotide; Protein Kinase C; Protein Kinase C-theta; Proto-Oncogene Proteins c-ets; Ramipril; Repressor Proteins; Telmisartan; White People | 2013 |
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Risk; Telmisartan | 2013 |
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diet; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Feeding Behavior; Female; Follow-Up Studies; Global Health; Glomerular Filtration Rate; Humans; Incidence; Male; Middle Aged; Prospective Studies; Ramipril; Renal Insufficiency, Chronic; Risk Factors; Telmisartan; Time Factors | 2013 |
Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Body Weight; Circadian Rhythm; Female; Humans; Hypertension; Male; Meta-Analysis as Topic; Middle Aged; Ramipril; Retrospective Studies; Telmisartan | 2014 |
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Creatinine; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Hypertension; Hypokalemia; Kidney; Kidney Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nonlinear Dynamics; Odds Ratio; Potassium; Proportional Hazards Models; Ramipril; Renal Dialysis; Renin-Angiotensin System; Risk Assessment; Risk Factors; Stroke; Telmisartan; Time Factors; Treatment Outcome | 2014 |
The mini-mental state examination, clinical factors, and motor vehicle crash risk.
Topics: Accidents, Traffic; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Automobile Driving; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dementia; Diabetes Complications; Female; Humans; Male; Neuropsychological Tests; Predictive Value of Tests; Prospective Studies; Ramipril; Risk; Telmisartan | 2014 |
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Coronary Artery Disease; Diastole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Ramipril; Stroke; Systole; Telmisartan; Time Factors; Treatment Outcome | 2015 |
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.
Topics: Aged; Aged, 80 and over; Aging; Benzimidazoles; Benzoates; Cardiovascular Diseases; Chronic Disease; Cognition Disorders; Dementia; Disabled Persons; Female; Glucose Metabolism Disorders; Humans; Male; Middle Aged; Ramipril; Risk Factors; Telmisartan | 2015 |
Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Carotid Arteries; Cysteine; Drug Combinations; Female; Homocysteine; Humans; Male; Middle Aged; Ramipril; Renal Insufficiency, Chronic; Telmisartan; Tunica Intima | 2016 |
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Odds Ratio; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan; Time Factors; Treatment Outcome | 2017 |
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Ramipril; Risk Assessment; Single-Blind Method; Stroke; Telmisartan; Treatment Outcome | 2018 |
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus; Diastole; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Hypertension; Myocardial Infarction; Peripheral Arterial Disease; Ramipril; Retrospective Studies; Risk Factors; Stroke; Systole; Telmisartan | 2019 |
Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Eggs; Female; Humans; Lipids; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Ramipril; Telmisartan | 2020 |
75 other study(ies) available for telmisartan and ramipril
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Preventing cardiovascular diseases. Discovering the optimal approach].
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Coronary Artery Disease; Coronary Vessels; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2001 |
[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Hypertrophy, Left Ventricular; Ramipril; Renal Insufficiency; Telmisartan | 2003 |
[Therapy of hypertension. Lasting organ protection moves into the foreground].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Myocardial Infarction; Ramipril; Receptor, Angiotensin, Type 1; Stroke; Telmisartan; Treatment Outcome | 2003 |
[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; Humans; Myocardial Infarction; Placebos; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Time Factors | 2003 |
Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arterioles; Benzimidazoles; Benzoates; Cerebral Arteries; Cerebrovascular Circulation; Homeostasis; Hypertension; Male; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Telmisartan; Vasodilation | 2005 |
Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Oxidation-Reduction; Ramipril; Telmisartan | 2005 |
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-6; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monocytes; Pyrroles; Ramipril; Renin-Angiotensin System; Telmisartan | 2005 |
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Metabolic Syndrome; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Time Factors | 2006 |
[Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2007 |
ACE inhibitors in cardiovascular disease--unbeatable?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Research Design; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cataract; Female; Hearing Loss, Sensorineural; Humans; Kidney Diseases; Losartan; Male; Molecular Motor Proteins; Mutation; Myosin Heavy Chains; Proteinuria; Ramipril; Renin-Angiotensin System; Syndrome; Telmisartan; Thrombocytopenia | 2008 |
ONTARGET: questions asked, questions answered.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome | 2008 |
[What is better here: ACE inhibitor or AT1 blocker?].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2008 |
A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Benzimidazoles; Benzoates; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Indapamide; Perindopril; Ramipril; Telmisartan | 2008 |
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Body Size; Cardiovascular Diseases; Humans; Life Style; Metabolic Syndrome; Obesity; Ramipril; Renin-Angiotensin System; Risk Assessment; Risk Factors; Telmisartan | 2008 |
[Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan | 2008 |
Telmisartan, ramipril, or both in patients at high risk of vascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus; Drug Therapy, Combination; Humans; Ramipril; Telmisartan | 2008 |
Telmisartan, ramipril, or both in patients at high risk of vascular events.
Topics: Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypotension; Ramipril; Telmisartan | 2008 |
[No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Telmisartan; Treatment Outcome | 2008 |
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Research Design; Telmisartan; Treatment Outcome | 2008 |
[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypotension; Ramipril; Risk Assessment; Risk Factors; Telmisartan | 2008 |
Renin-angiotensin blockade and kidney disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan | 2008 |
Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Clinical Trials, Phase IV as Topic; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Stroke; Telmisartan; Treatment Outcome | 2008 |
[ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Evidence-Based Medicine; Follow-Up Studies; Humans; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2008 |
Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.
Topics: Adiponectin; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Cohort Studies; Confidence Intervals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertension, Renal; Male; Middle Aged; Ramipril; Telmisartan | 2008 |
Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Nitric Oxide; p-Aminohippuric Acid; Ramipril; Renal Plasma Flow; Telmisartan; Vascular Resistance | 2009 |
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Kidney Diseases; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan | 2008 |
ONTARGET: How much RAS inhibition is enough?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Humans; Kidney Diseases; Ramipril; Renin-Angiotensin System; Telmisartan | 2009 |
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Cardiovascular Diseases; Cognition; Cognition Disorders; Cross-Sectional Studies; Depression; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan | 2009 |
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Ramipril; Renal Insufficiency; Risk; Stroke; Telmisartan; Treatment Outcome | 2009 |
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
Topics: Acrylates; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Enalapril; Humans; Imidazoles; Indazoles; Lisinopril; Male; Mice; Mice, SCID; Neoplasms; Nifedipine; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Ramipril; Rats; Rats, Sprague-Dawley; Telmisartan; Thiophenes; Xenograft Model Antitumor Assays | 2009 |
[The ONTARGET trial].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk Factors; Telmisartan; Treatment Outcome | 2009 |
Clinical practice guides.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Data Interpretation, Statistical; Humans; Myocardial Ischemia; Ramipril; Randomized Controlled Trials as Topic; Statistics as Topic; Telmisartan | 2009 |
Focus on the ONTARGET results.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Male; Ramipril; Renin-Angiotensin System; Telmisartan | 2009 |
Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan | 2009 |
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Ramipril; Retrospective Studies; Risk Factors; Telmisartan | 2009 |
Cardiovascular protection: a breakthrough for high-risk patients?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan | 2009 |
Proteinuria: Is the ONTARGET renal substudy actually off target?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Disease Progression; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney; Multicenter Studies as Topic; Proteinuria; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2009 |
Is therapy of people with chronic kidney disease ONTARGET?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney Diseases; Ramipril; Telmisartan; Treatment Outcome | 2010 |
ONTARGET should not be over interpreted.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney Diseases; Ramipril; Telmisartan; Treatment Outcome | 2010 |
New data on ONTARGET: more confusion?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2010 |
Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Brain Ischemia; Cerebral Arteries; Drug Therapy, Combination; Hypertension; Male; Ramipril; Random Allocation; Rats; Rats, Inbred SHR; Telmisartan; Vasodilation | 2010 |
Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arterioles; Benzimidazoles; Benzoates; Blood Pressure; Cerebrovascular Circulation; Drug Therapy, Combination; Hypertension; Male; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Telmisartan | 2010 |
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.
Topics: Albumins; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Drug Combinations; Female; Humans; Male; Potassium; Ramipril; Statistics, Nonparametric; Telmisartan | 2010 |
Simultaneous determination of ramipril, ramiprilat and telmisartan in human plasma using liquid chromatography tandem mass spectrometry.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Chemical Analysis; Chromatography, Liquid; Humans; Ramipril; Tandem Mass Spectrometry; Telmisartan; Time Factors | 2011 |
Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Humans; Ramipril; Renin-Angiotensin System; Telmisartan | 2010 |
Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Cholesterol; Drug Therapy, Combination; Endothelium, Vascular; Erectile Dysfunction; Free Radicals; Lipid Peroxides; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; Ramipril; Renin-Angiotensin System; Telmisartan | 2011 |
Telmisartan in high-risk cardiovascular patients. No need to change standard practice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Ramipril; Risk Factors; Telmisartan | 2011 |
New clinical concepts after the ONTARGET trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ramipril; Telmisartan | 2011 |
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Male; Ramipril; Random Allocation; Rats; Rats, Inbred SHR; Rats, Wistar; Stroke; Telmisartan | 2011 |
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cost of Illness; Diabetes Complications; Health Services; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan | 2011 |
Is a blood pressure target of <130/80 mm Hg still appropriate for high-risk patients?
Topics: Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Guidelines as Topic; Humans; Kidney Diseases; Ramipril; Telmisartan | 2011 |
Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.
Topics: Adipose Tissue; Adrenocorticotropic Hormone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Corticosterone; Drug Therapy, Combination; Feeding Behavior; Heart Rate; Leptin; Male; Obesity; Ramipril; Rats; Rats, Inbred SHR; Telmisartan; Weight Gain | 2012 |
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Ramipril; Telmisartan | 2011 |
[High blood pressure in the morning].
Topics: Benzimidazoles; Benzoates; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Ramipril; Telmisartan | 2011 |
Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Pressure; Cardiomegaly; Drug Therapy, Combination; Endothelial Cells; Fibrosis; Male; Mice; Mice, Inbred C57BL; Myocardium; Ramipril; Stem Cells; Telmisartan | 2013 |
Is there room for dual blockade of the renin-angiotensin-aldosterone system?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Humans; Ramipril; Renin-Angiotensin System; Telmisartan | 2012 |
Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension.
Topics: Atrial Fibrillation; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Male; Ramipril; Telmisartan | 2012 |
Renal outcome in equipotent antihypertensive treatment with telmisartan, ramipril and in combination in SHR-SP rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Drug Therapy, Combination; Kidney Function Tests; Organ Size; Ramipril; Rats; Rats, Inbred SHR; Survival Rate; Telmisartan | 2012 |
[Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Coronary Vasospasm; Drug Therapy, Combination; Early Termination of Clinical Trials; Fumarates; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Renin; Renin-Angiotensin System; Telmisartan | 2012 |
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.
Topics: Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Blood Pressure; Cyclooxygenase 2 Inhibitors; Desoxycorticosterone Acetate; Disease Models, Animal; Etoricoxib; Hypertension; Mineralocorticoids; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Sodium Chloride; Sulfones; Telmisartan | 2013 |
Acute regulation of pancreatic islet microcirculation and glycaemia by telmisartan and ramipril: discordant effects between normal and type 2 diabetic rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Mellitus, Type 2; Insulin; Islets of Langerhans; Male; Microcirculation; Pancreas; Ramipril; Rats; Rats, Wistar; Regional Blood Flow; Renin-Angiotensin System; Telmisartan | 2013 |
Moving dietary management of diabetes forward.
Topics: Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diet; Feeding Behavior; Female; Humans; Male; Ramipril; Renal Insufficiency, Chronic; Telmisartan | 2013 |
[Effect of RAAS antagonist on the expression of gap junction cx43 in myocardium of spontaneously hypertensive rat].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Connexin 43; Eplerenone; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Ramipril; Rats; Rats, Inbred SHR; Rats, Wistar; Renin-Angiotensin System; Spironolactone; Telmisartan | 2013 |
Systolic blood pressure target levels: evidence for benefits in stroke.
Topics: Benzimidazoles; Benzoates; Blood Pressure; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Ramipril; Stroke; Telmisartan | 2015 |
Recent clinical trials.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2014 |
Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dihydropyridines; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Perindopril; Propensity Score; Ramipril; Retrospective Studies; Risk Factors; Telmisartan; Tetrazoles | 2015 |
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Cognition Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Ramipril; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Telmisartan | 2015 |
Use of Health Care Databases to Support Supplemental Indications of Approved Medications.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Delivery of Health Care; Drug Approval; Drug Prescriptions; Follow-Up Studies; Humans; Ramipril; Retrospective Studies; Telmisartan; United States | 2018 |
Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; COVID-19; Diabetes Mellitus, Experimental; Diet, High-Fat; Immunoblotting; In Situ Hybridization; Kidney; Lung; Male; Mice; Ramipril; Receptors, Coronavirus; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Serine Endopeptidases; Telmisartan | 2021 |
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Antihypertensive Agents; Czech Republic; Heart Failure; Humans; Losartan; Neprilysin; Perindopril; Ramipril; Retrospective Studies; Telmisartan; Valsartan | 2022 |
Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Electronic Health Records; Ethnicity; Humans; Minority Groups; Ramipril; Telmisartan; United Kingdom | 2022 |
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Amlodipine; Amphotericin B; Australia; Case-Control Studies; Ciprofloxacin; Diclofenac; Furosemide; Humans; Ibuprofen; Metformin; Naproxen; Omeprazole; Primary Health Care; Ramipril; Simvastatin; Spironolactone; Sulfamethoxazole; Telmisartan; Trimethoprim; Valacyclovir; Zoledronic Acid | 2022 |